Lanadelumab

TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.

Who should not take it

None.

Other medicines and interactions

No dedicated drug interaction studies have been conducted.

Storing it

Storage and Handling

Store the prefilled syringes and vials refrigerated at 36°F to 46°F (2°C to 8°C).
Do not freeze. Do not shake.
Keep the prefilled syringe and vial in the original carton to protect from light.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Lanadelumab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lanadelumab
APA 7th: sofidex. (2026, August 3). Lanadelumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lanadelumab
AMA 11th: Lanadelumab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lanadelumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.